Details of the Drug Combination

General Information of Drug Combination (ID: DCTRY48)

Drug Combination Name
Estramustine Pentostatin
Indication
Disease Entry Status REF
Melanoma Investigative [1]
Component Drugs Estramustine   DMWTAOI Pentostatin   DM0HXDS
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: SK-MEL-2
Zero Interaction Potency (ZIP) Score: 0.24
Bliss Independence Score: 3.26
Loewe Additivity Score: 1.46
LHighest Single Agent (HSA) Score: 1.74

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Estramustine
Disease Entry ICD 11 Status REF
Prostate cancer 2C82.0 Approved [2]
Estramustine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Estramustine binding protein (EMBP) TTSBFYK NOUNIPROTAC Binder [5]
------------------------------------------------------------------------------------
Estramustine Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [6]
------------------------------------------------------------------------------------
Estramustine Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Keratin, type I cytoskeletal 18 (KRT18) OTVLQFIP K1C18_HUMAN Increases Expression [7]
------------------------------------------------------------------------------------
Indication(s) of Pentostatin
Disease Entry ICD 11 Status REF
Acute graft versus host disease 4B24.0 Approved [3]
Hairy cell leukaemia 2A82.2 Approved [4]
Leukemia N.A. Approved [3]
Pentostatin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Adenosine deaminase (ADA) TTLP57V ADA_HUMAN Inhibitor [8]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Childhood T acute lymphoblastic leukemia DCD6IRM CCRF-CEM Investigative [9]
Clear cell renal cell carcinoma DCYBVPU TK-10 Investigative [9]
Glioblastoma DCZPBBD SNB-75 Investigative [9]
Plasma cell myeloma DCU3HIR RPMI-8226 Investigative [9]
Carcinoma DCWQG7C RXF 393 Investigative [10]
Carcinoma DCPXYQ4 MCF7 Investigative [10]
Colon carcinoma DCIKBP8 KM12 Investigative [10]
Invasive ductal carcinoma DCG92UG HS 578T Investigative [10]
Adenocarcinoma DCJWJ1Y NCIH23 Investigative [1]
High grade ovarian serous adenocarcinoma DCWPTJB OVCAR-4 Investigative [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 10 DrugCom(s)

References

1 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125976
2 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
3 Pentostatin FDA Label
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4805).
5 Estramustine binding protein in primary tumours and metastases of malignant melanoma. Melanoma Res. 1994 Dec;4(6):401-5.
6 Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts. J Urol. 2003 May;169(5):1729-34.
7 Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles. Br J Cancer. 2006 Jun 5;94(11):1592-8. doi: 10.1038/sj.bjc.6603129.
8 Purine nucleoside analogs in indolent non-Hodgkin's lymphoma. Oncology (Williston Park). 2000 Jun;14(6 Suppl 2):13-5.
9 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
10 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1126165